Global Fluoxetine Market, By Drug Class (Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)), Application (Obsessive-Compulsive Disorder, Panic Disorder, Depression, Bulimia Nervosa, Others), Demographic (Adult, Pediatric, Geriatric), Dosage Form (Tablet, Solution, Capsule, Syrup, Others), Route of Administration (Oral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Fluoxetine market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 4.10% in the above mentioned forecast period.
Fluoxetine is selective serotonin reuptake inhibitor (SSRI) antidepressant which works by blocking the reuptake of SSRI by neurons. It is referred to a prescription drug which is available in various dosage forms including tablet, solution, capsule, syrup, and delayed-release capsule. It is also available as generic drug. Sarafem, prozac, selfemra and prozac weekly are the brand names for this drug. This medication is helpful in the treatment of obsessive-compulsive disorder, panic disorder, depression, bulimia nervosa and premenstrual dysphoric disorder (PMDD).
The rise in the prevalence of bulimia nervosa and obsessive-compulsive disorder will act a major driver for the expansion of fluoxetine market. Furthermore, increasing geriatric population, rising healthcare expenditure and increase in the number of patients suffering from depression are the factors that will expand the fluoxetine market. Other factors including rise in the growing government initiatives, changing lifestyle and rising awareness will positively impact the market growth rate.
Moreover, the rise in the research and development activities, new product launches and strategic collaborations will provide beneficial opportunities for the fluoxetine market in the forecast period of 2021-2028.
However, high cost of drug, and side effects associated with fluoxetine such as loss of appetite, diarrhea, headache, nausea, dizziness, seizures and other. All these factors hamper the market growth. Lack of awareness and intense competition among market players will further challenge the fluoxetine market in the forecast period mentioned above.
This fluoxetine market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the fluoxetine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Fluoxetine Market Scope and Market Size
The fluoxetine market is segmented on the basis of drug class, application, demographic, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of drug class, the fluoxetine market is segmented into antidepressant, selective serotonin reuptake inhibitor (SSRI).
- On the basis of application, the fluoxetine market is segmented into obsessive-compulsive disorder, panic disorder, depression, bulimia nervosa and others.
- On the basis of demographic, the fluoxetine market is segmented into adult, pediatric and geriatric.
- On the basis of dosage form, the fluoxetine market is segmented into tablet, solution, capsule, syrup, and others. Tablet segment is further sub-segmented into 10mg, 20mg, and 60mg. Capsule segment is further sub-segmented into 10mg, 20mg, and 40mg. Solution segment is further sub-segmented into 20mg/5ml and others.
- On the basis of route of administration, the fluoxetine market is segmented into oral and others.
- On the basis of end-users, the fluoxetine market is segmented into clinic, hospital and others.
The fluoxetine market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Fluoxetine Market Country Level Analysis
Fluoxetine market is analyzed and market size information is provided by the country, drug class, application, demographic, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the fluoxetine market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the fluoxetine market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing research and development activities and growing government support in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Fluoxetine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Fluoxetine Market Share Analysis
Fluoxetine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to fluoxetine market research.
Some of the major players operating in the fluoxetine market are Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Mylan N.V., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, WOCKHARDT, Alembic Pharmaceuticals Limited, Lannett, Pharmaceutical Associates Inc., Alvogen, Torrent Pharmaceuticals Ltd., Suzhou Yushi Pharmaceutical Co., Ltd., Apotex Inc., Accord Healthcare, ANGITA, and Changzhou Siyao Pharmaceuticals Co. Ltd., among others.